Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shigetec
- Development stage
- Phase 2
- Lead developer
- Eveliqure Biotechnologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
ShigETEC is a live, attenuated oral combination vaccine candidate designed to protect against infections caused by *Shigella* species and enterotoxigenic *Escherichia coli* (ETEC), two major causes of diarrheal disease worldwide. The vaccine strain is a non-invasive *Shigella* that lacks the LPS O-antigen and expresses ETEC toxoids. This design enables immune recognition of conserved antigens shared among different types of *Shigella* and ETEC, potentially providing broad protection. Oral immunization with ShigETEC has been shown in Phase 1 clinical trials to be well tolerated and safe up to four doses at 5 × 10^10 CFU, inducing robust systemic and mucosal immune responses against both pathogens. The vaccine is being developed for use in travelers, military personnel visiting endemic regions, and children in low- and middle-income countries.
- Other names
- ShigETEC live, attenuated, oral vaccine
02
Targets
ST (Heat-stable enterotoxin of enterotoxigenic Escherichia coli)LTB (Heat-labile enterotoxin B subunit)
Beyond the preview
Go deeper on shigetec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shigetec.